Document is current
Any future updates will be listed below
-
Authors
Hampel, Paul J. https://orcid.org/0000-0003-1292-3024
Rabe, Kari G. https://orcid.org/0000-0002-7313-1875
Wang, Yucai https://orcid.org/0000-0002-1576-8341
Hwang, Steven R.
Kenderian, Saad S. https://orcid.org/0000-0003-2767-3830
Muchtar, Eli https://orcid.org/0000-0003-2210-2174
Leis, Jose F.
Koehler, Amber B.
Tsang, Mazie
Hilal, Talal
Parrondo, Ricardo https://orcid.org/0000-0002-9314-9933
Bailen, Rachel J. https://orcid.org/0000-0003-0591-5843
Schwager, Susan M.
Hanson, Curtis A.
Braggio, Esteban https://orcid.org/0000-0003-3860-4830
Slager, Susan L. https://orcid.org/0000-0002-5173-4712
Shi, Min https://orcid.org/0000-0002-5741-4293
Zepeda-Mendoza, Cinthya J.
Van Dyke, Daniel L.
Shanafelt, Tait D.
King, Rebecca L.
Call, Timothy G.
Kay, Neil E. https://orcid.org/0000-0002-5951-5055
Ding, Wei https://orcid.org/0000-0001-9811-4601
Parikh, Sameer A. https://orcid.org/0000-0002-3221-7314
- License Information
-
More Information
Article History
Received: 24 June 2024
Revised: 25 October 2024
Accepted: 29 November 2024
First Online: 10 December 2024
Competing interests
: The authors declare no competing financial interests in direct relation to the work reported. The following authors also declare no competing financial interests otherwise: PJH, KGR, SRH, JFL, RP, RJB, SMS, MT, CAH, MS, CJZM, DLV, EB, SLS, RBK, TGC. In the interest of transparency, additional potential conflicts of interest for the remaining authors are included below. TH: Consultancy for BeiGene. Research funding provided to the institution from BeiGene. YW: Membership on Board of Directors or advisory committees for Incyte, InnoCare, LOXO Oncology, Eli Lilly, TG Therapeutics, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie (compensation to institution). Research funding (to institution) from Incyte, InnoCare, LOXO Oncology, Eli Lilly, Novartis, Genentech, MorphoSys, GenMab, AbbVie. Honorarium (to institution) from Kite. SSK: Patents and royalties from Novartis, Humanigen, Mettafforgr, Sendero, and MustangBio; Research funding from Kite, Gilead, Juno, BMS, Novartis, Humanigen, MorphoSys, Tolero, Sunesis/Viracta, LifEngine Animal Health Laboratories Inc, and Lentigen; Scientific advisory boards in Kite/Gilead, Calibr, Luminary Therapeutics, Humanigen, Juno/BMS, Capstan Bio, and Novartis; DSMB: Humanigen, Carisma; Consultancy: Torque, Calibr, Novartis, Capstan Bio, and Humanigen. EM: Honorarium from Janssen. Consultation fee from Protego (paid to the institution). SA: Consultancy for BMS, Janssen, Amgen, Pharmacyclics, GSK, Takeda, Genentech, AbbVie, Karyopharm, Beigene, Sanofi. Research funding from BMS, Janssen, Amgen, Pharmacyclics, Ascentage, Medimmune, Cellectar, Xencor, GSK. ABK: Membership on Board of Directors or advisory committees for AbbVie and TG Therapeutics. TDS: Research funding from Abbvie, Genentech, and Pharmacyclics. NEK: Membership on Board of Directors or advisory committees for Abbvie, BMS, Celgene, Pharmacyclics, AstraZeneca, Behring, CytomX Therapeutics, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Targeted Oncology, Agios Pharm, Morpho-sys, Rigel. Research funding from Abbvie, Acerta Pharma, BMS, Celgene, Genentech, MEI Pharma, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. WD: Employment with BeiGene. Research funding has been provided to the institution from Merck and DTRM. Participation in advisory board meetings for Merck and Octapharma. SAP: Research funding has been provided to the institution from Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria has been provided to the institution from Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, Amgen, MingSight Pharmaceuticals, Ascentage Pharma, Eli Lilly, TG Therapeutics, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings.
